Tarsus Pharmaceuticals (TARS) Income from Continuing Operations (2019 - 2026)

Tarsus Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 6880000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 72.52% year-over-year to 6880000.0; the TTM figure through Mar 2026 stood at 45998000.0 (up 55.3% YoY), while the FY2025 annual figure was 66418000.0, up 42.52% from the prior year.
• Income from Continuing Operations was 6880000.0 for Q1 2026 at Tarsus Pharmaceuticals, down from 6240000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 5471000.0 in Q2 2022 to a low of 42461000.0 in Q4 2023.
• Historically, Income from Continuing Operations has averaged 22471529.41 across 5 years, with a median of 23086000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 474.12% in 2023, then soared 72.97% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 13626000.0 in 2022, then slumped by 211.62% to 42461000.0 in 2023, then surged by 45.63% to 23086000.0 in 2024, then surged by 72.97% to 6240000.0 in 2025, then dropped by 10.26% to 6880000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 6880000.0 (Q1 2026), 6240000.0 (Q4 2025), and 12683000.0 (Q3 2025), per Business Quant data.